Sees FY23 revenue $7.94B-$8.34B, consensus $8.15B. CEO Steve Cutler commented, "ICON’s achievements in advancing the speed and efficiency of clinical development continue to progress as we support an ever-growing number of customer partnerships, and we are pleased with our strong operational delivery and cost management in 2022. Our outlook for 2023 reflects a continued solid demand environment albeit with persistent macroeconomic challenges, resulting in full year revenue guidance in the range of $7,940 – $8,340 million and adjusted earnings per share1 guidance in the range of $12.40 – $13.05."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ICLR: